About two weeks after announcing success in the first Phase III trial of its platelet drug fostamatinib in chronic/persistent immune thrombocytopenia, Rigel Pharmaceuticals Inc. announced a 38% staff reduction, more or less gutting its R&D division to add a nearly equivalent headcount in commercial personnel.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?